4,552 results match your criteria efficacy rituximab


Prognostic significance of FCGR2B expression for the response of DLBCL patients to rituximab or obinutuzumab treatment.

Blood Adv 2021 Aug;5(15):2945-2957

School of Cancer Sciences, University of Southampton, Southampton, United Kingdom.

Fc γ receptor IIB (FcγRIIB) is an inhibitory molecule capable of reducing antibody immunotherapy efficacy. We hypothesized its expression could confer resistance in patients with diffuse large B-cell lymphoma (DLBCL) treated with anti-CD20 monoclonal antibody (mAb) chemoimmunotherapy, with outcomes varying depending on mAb (rituximab [R]/obinutuzumab [G]) because of different mechanisms of action. We evaluated correlates between FCGR2B messenger RNA and/or FcγRIIB protein expression and outcomes in 3 de novo DLBCL discovery cohorts treated with R plus cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) reported by Arthur, Schmitz, and Reddy, and R-CHOP/G-CHOP-treated patients in the GOYA trial (NCT01287741). Read More

View Article and Full-Text PDF

Single-nucleotide Fcγ receptor polymorphisms do not impact obinutuzumab/rituximab outcome in patients with lymphoma.

Blood Adv 2021 Aug;5(15):2935-2944

School of Cancer Sciences, Faculty of Medicine, University of Southampton, Southampton, United Kingdom.

Single-nucleotide polymorphisms (SNPs) have been shown to influence Fcγ receptor (FcγR) affinity and activity, but their effect on treatment response is unclear. We assessed their importance in the efficacy of obinutuzumab or rituximab combined with chemotherapy in untreated advanced follicular lymphoma (FL) and diffuse large B-cell lymphoma (DLBCL) in the GALLIUM (www.clinicaltrials. Read More

View Article and Full-Text PDF

Safety and efficacy of azathioprine in immune thrombocytopenia.

Am J Blood Res 2021 15;11(3):217-226. Epub 2021 Jun 15.

Department of Clinical Hematology and Stem Cell Transplant, Army Hospital (Research & Referral) Delhi, India.

Background: Immune thrombocytopenia (ITP) is a benign hematological disorder characterized by low platelet counts in peripheral blood and spectrum of various bleeding manifestations. Azathioprine is one of the effective, readily available, and affordable immunosupressants available for ITP management in developing countries. We aimed to study the efficacy and long-term safety profile of our patients with ITP who were treated with azathioprine. Read More

View Article and Full-Text PDF

Obinutuzumab Plus Chemotherapy Compared with Rituximab Plus Chemotherapy in Previously Untreated Italian Patients with Advanced Follicular Lymphoma at Intermediate-High Risk: A Cost-Effectiveness Analysis.

Clinicoecon Outcomes Res 2021 22;13:661-671. Epub 2021 Jul 22.

Market Access Department, Roche SpA, Monza, Italy.

Objective: To assess the cost-effectiveness of obinutuzumab (O-chemo) in comparison to rituximab (R-chemo) in patients with untreated advanced follicular lymphoma (FL) at intermediate or high risk from an Italian National Health Service (NHS) perspective.

Methods: A previously developed four-state Markov model was adapted to estimate lifetime clinical outcomes and costs of Italian patients with advanced FL and an FL international predictive index score ≥2 in treatment with O-chemo and R-chemo. Life expectancy was derived from the GALLIUM and PRIMA clinical trials. Read More

View Article and Full-Text PDF

Rituximab for the Treatment of Refractory Cardiac Sarcoidosis-A Single Center Experience.

J Card Fail 2021 Jul 25. Epub 2021 Jul 25.

Division of Rheumatology, Department of Medicine, Mayo Clinic, Rochester, MN, USA; Division of Epidemiology, Department of Health Sciences Research, Rochester, MN, USA.

Objective: To examine the effect of anti-B cell therapy (rituximab) on cardiac inflammation and function in corticosteroid-refractory cardiac sarcoidosis.

Background: Cardiac sarcoidosis (CS) is a rare cause of cardiomyopathy characterized by granulomatous inflammation involving the myocardium. While typically responsive to corticosteroid treatment, there is a critical need for identifying effective steroid-sparing agents for disease control. Read More

View Article and Full-Text PDF

Rituximab use in pediatric systemic lupus erythematosus: Indications, efficacy and safety in an Indian cohort.

Lupus 2021 Jul 27:9612033211034567. Epub 2021 Jul 27.

Division of Pediatric Rheumatology, 28928Sir Ganga Ram Hospital, Institute of Child Health, Sir Ganga Ram Hospital, New Delhi, India.

Children with systemic lupus erythematosus have a more challenging and difficult course as compared to their adult counterparts. Today, the aim of therapy for any child with lupus is to keep the child in a state of sustained remission with minimal or no use of steroids. This laudable goal is often difficult to achieve for the child with lupus. Read More

View Article and Full-Text PDF

Romiplostim in children with newly diagnosed or persistent primary immune thrombocytopenia.

Ann Hematol 2021 Jul 26. Epub 2021 Jul 26.

Centre for Haematology, Department of Immunology and Inflammation, Imperial College London, London, UK.

Immune thrombocytopenia (ITP) is a disease of heterogenous origin characterized by low platelet counts and an increased bleeding tendency. Three disease phases have been described: newly diagnosed (≤ 3 months after diagnosis), persistent (> 3-12 months after diagnosis), and chronic (> 12 months after diagnosis). The majority of children with ITP have short-lived disease and will not need treatment. Read More

View Article and Full-Text PDF

Non-clinical similarity of biosimilar ABP 798 with rituximab reference product.

Biologicals 2021 Jul 21. Epub 2021 Jul 21.

Amgen Inc., One Amgen Center Drive, Thousand Oaks, CA, 91320, USA. Electronic address:

ABP 798 is a biosimilar to Rituxan® (rituximab reference product [RP]). Non-clinical assessments relevant to the primary and secondary mechanisms of action (MOA) contribute to the totality of the evidence (TOE) in supporting biosimilarity and are critical in providing scientific evidence for extrapolation of indications. Similarity of ABP 798 with rituximab RP was investigated across a range of biological activities which have potential impact on pharmacokinetics and clinical efficacy with non-clinical assessments relevant to MOA such as CD20 internalization, trogocytosis, binding to primary human natural killer (NK) cells as well as the ability to induce antibody-dependent cellular phagocytosis (ADCP) in peripheral blood mononuclear cells. Read More

View Article and Full-Text PDF

NMR Spectroscopy for Protein Higher Order Structure Similarity Assessment in Formulated Drug Products.

Molecules 2021 Jul 13;26(14). Epub 2021 Jul 13.

Division of Complex Drug Analysis, Office of Testing and Research, Office of Pharmaceutical Quality, Center for Drug Evaluation and Research, U.S. Food and Drug Administration, Silver Spring, MD 20993, USA.

Peptide and protein drug molecules fold into higher order structures (HOS) in formulation and these folded structures are often critical for drug efficacy and safety. Generic or biosimilar drug products (DPs) need to show similar HOS to the reference product. The solution NMR spectroscopy is a non-invasive, chemically and structurally specific analytical method that is ideal for characterizing protein therapeutics in formulation. Read More

View Article and Full-Text PDF

THE 2021 EUROPEAN GROUP ON GRAVES' ORBITOPATHY (EUGOGO) CLINICAL PRACTICE GUIDELINES FOR THE MEDICAL MANAGEMENT OF GRAVES' ORBITOPATHY.

Eur J Endocrinol 2021 Jul 1. Epub 2021 Jul 1.

W Wiersinga, Endocrinology and Metabolism, AMC, Amsterdam, 1105 AZ, Netherlands.

Graves' orbitopathy (GO) is the main extrathyroidal manifestation of Graves' disease (GD). Choice of treatment should be based on assessment of clinical activity and severity of GO. Early referral to specialized centers is fundamental for most patients with GO. Read More

View Article and Full-Text PDF

Noninfectious, Severe Cryoglobulinemic Vasculitis with Renal Involvement - Safety and Efficacy of Long-Term Treatment with Rituximab.

Int J Nephrol Renovasc Dis 2021 16;14:267-277. Epub 2021 Jul 16.

Department of Internal Medicine, Nephrology and Dialysis, Military Institute of Medicine, Warsaw, Poland.

Background: The management of nonviral cryoglobulinemic vasculitis (CV) has not been established yet. Randomized control trials are challenging to perform because of the rarity of the disease. The most promising biological therapy is rituximab (RTX), an anti-CD 20 monoclonal antibody. Read More

View Article and Full-Text PDF

Dose-Adjusted Epoch and Rituximab for the treatment of double expressor and double hit diffuse large B-cell lymphoma: impact of TP53 mutations on clinical outcome.

Haematologica 2021 Jul 22. Epub 2021 Jul 22.

Department of Hematology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milano; Chair of Hematology University of Milano.

Diffuse Large B-Cell Lymphoma (DLBCL) is a heterogeneous disease, including one-third of cases overexpressing MYC and BCL2 proteins (Double Expressor Lymphoma, DEL) and 5-10% of patients with chromosomal rearrangements of MYC, BCL2 and/or BCL-6 (Double/Triple-Hit Lymphomas, DH/TH). TP53 mutations are detected in 20-25% of DEL. We report the efficacy of dose-adjusted EPOCH and rituximab (DA-EPOCH-R) in a series of 122 consecutive patients, including DEL (n=81, 66%), DEL-MYC (n=9, 7%), DEL-BCL2 (n=13, 11%), or High-Grade Lymphomas (DH/TH) (n=19, 16%). Read More

View Article and Full-Text PDF

A systematic review on efficacy, safety, and treatment-durability of low-dose rituximab for the treatment of Pemphigus: special focus on COVID-19 pandemic concerns.

Immunopharmacol Immunotoxicol 2021 Jul 21:1-12. Epub 2021 Jul 21.

Department of Dermatology, Rasool Akram Medical Complex, Iran University of Medical Sciences, Tehran, Iran.

Background: Rituximab is a FDA-approved monoclonal antibody for adults with moderate to severe potentially life-threatening pemphigus vulgaris. Recent studies have focused on assessments of efficacy and safety of low-dose rituximab (<2 gram in each cycle).

Method: Databases were searched from 2010 to 2020 (last update: 1 June 2020). Read More

View Article and Full-Text PDF

Low-dose immune tolerance induction alone or with immunosuppressants according to prognostic risk factors in Chinese children with hemophilia A inhibitors.

Res Pract Thromb Haemost 2021 Jul 14;5(5):e12562. Epub 2021 Jul 14.

Hemophilia Comprehensive Care Center Hematology Center Beijing Key Laboratory of Pediatric Hematology Oncology National Key Discipline of Pediatrics (Capital Medical University) Key Laboratory of Major Diseases in Children Ministry of Education Beijing Children's Hospital National Center for Children's Health Capital Medical University Beijing China.

Background: In developing countries, children with hemophilia A (HA) with high-titer inhibitor and poor immune tolerance induction (ITI) prognostic risk(s) cannot afford the recommended high- or intermediate-dose ITI.

Objectives: To determine the efficacy of low-dose ITI (plasma-derived factor VIII [FVIII]/von Willebrand factor at 50 FVIII IU/kg every other day) by itself (ITI-alone) or combined with immunosuppressants rituximab and prednisone (ITI-IS) in children with HA with high-titer inhibitor.

Methods: All enrolled patients had pre-ITI inhibitor ≥10 BU. Read More

View Article and Full-Text PDF

Management of Relapsed Hairy Cell Leukemia: A Systematic Review of Novel Agents and Targeted Therapies.

Clin Lymphoma Myeloma Leuk 2021 Jun 24. Epub 2021 Jun 24.

Department of Hematology-Oncology, Cleveland Clinic- Taussig Cancer Center, Cleveland, OH.

Background: Hairy cell leukemia (HCL) responds well to purine analogs with an overall median relapse free survival of 11-16 years. Most patients can be retreated with the same or a different purine analog however a subset of patients will become resistant or develop cumulative toxicities. Novel agents such as Vemurafenib (BRAF kinase inhibitor), Bendamustine/Rituximab (BR), Moxetumomab pasudotox (anti CD-22 recombinant immunotoxin) and Ibrutinib have emerging roles in patients with relapsed HCL. Read More

View Article and Full-Text PDF

Targeted and biological drugs in the treatment of inflammatory rheumatic diseases.

Authors:
Karel Pavelka

Vnitr Lek 2021 ;67(4):195-200

The aim of the review article is to provide an overview of biological and targeted drugs currently registered in the Czech Republic for the treatment of inflammatory rheumatic diseases. Specifically, the review deals with the treatment of rheumatoid arthritis (RA), ankylosing spondylitis (AS), and psoriatic arthritis (PsA). Five anti-TNF drugs as well as four biological drugs with a different mechanism of action (abatacept, rituximab, and two IL-6 inhibitors) are currently registered for the treatment of RA. Read More

View Article and Full-Text PDF

Comparative Efficacy of First-Line Treatments of Chronic Lymphocytic Leukemia: Network Meta-Analyses of Survival Curves.

Clin Lymphoma Myeloma Leuk 2021 Jun 23. Epub 2021 Jun 23.

Center for Health Outcomes and PharmacoEconomic Research, University of Arizona, Tucson, AZ; University of Arizona Cancer Center, Tucson, AZ; Department of Pharmacy Practice and Science, College of Pharmacy, University of Arizona, Tucson, AZ. Electronic address:

Background: Multiple treatment options in first-line chronic lymphocytic leukemia (CLL) pose a challenge in identifying the best treatment. We performed novel network meta-analyses (NMA; 8 trials, 11 treatments) on the Kaplan-Meier curves to compare treatments for fludarabine-ineligible patients on progression-free survival (PFS), time-to-next-treatment (TTNT) and overall survival (OS).

Methods: Using the Guyot method of enhanced secondary analysis of digitized survival data and applying the fixed lognormal distribution model, we extracted the survival proportions and hazard ratios (HR) over 60 months of follow-up, including PFS comparisons by unmutated/mutated IGHV and del 17p. Read More

View Article and Full-Text PDF

On the efficacy and safety of rituximab therapy in patients with systemic sclerosis disease: missing points, bottlenecks, over-exaggeration, and discrepancies-comments on the article by Moradzadeh et al.

Clin Rheumatol 2021 Jul 16. Epub 2021 Jul 16.

Department of Rheumatology and Clinical Immunology, University General Hospital of Larissa, Faculty of Medicine, School of Health Sciences, University of Thessaly, Larissa, Greece.

View Article and Full-Text PDF

Real-world Experience of Rituximab in Immune Thrombocytopenia.

Indian J Hematol Blood Transfus 2021 Jul 1;37(3):404-413. Epub 2021 Jan 1.

Department of Clinical Hematology and Stem Cell Transplant, Army Hospital (Research & Referral), New Delhi, 110010 India.

Immune thrombocytopenia (ITP) is a relapsing-remitting disease often requiring more than one line of therapy. Rituximab is a recommended second-line therapy, but the real-world data on its efficacy and safety from resource constraint settings is limited. We aimed to analyze the safety and efficacy of rituximab in ITP. Read More

View Article and Full-Text PDF

Long-term efficacy of rituximab in chronic ataxic neuropathy associated with anti-ganglioside antibodies.

Neurologia (Engl Ed) 2021 Jul 13. Epub 2021 Jul 13.

Unidad de Enfermedades Neuromusculares, Departamento de Neurología, Hospital del Mar, Barcelona, Spain. Electronic address:

View Article and Full-Text PDF

Fludarabine-Cyclophosphamide-Rituximab Treatment in Chronic Lymphocytic Leukemia, Focusing on Long Term Cytopenias Before and After the Era of Targeted Therapies.

Pathol Oncol Res 2021 27;27:1609742. Epub 2021 Apr 27.

Division of Hematology, Department of Internal Medicine, Faculty of Medicine, University of Debrecen, Debrecen, Hungary.

The widespread application of fludarabine, cyclophosphamide, and rituximab combination is limited due to its toxicity, particularly the prolonged cytopenias. The study aimed to compare the prolonged cytopenias depending on fitness and report real-life data on dose reduction measures and efficacy. According to our database, 120 and 14 patients were treated with FCR between 2011 and 2015 and between 2016 and 2019. Read More

View Article and Full-Text PDF

Anti-rituximab antibodies affect pharmacokinetics and pharmacodynamics of rituximab in children with immune-mediated diseases.

Clin Exp Rheumatol 2021 Jun 26. Epub 2021 Jun 26.

Department of Paediatric Immunology, Rheumatology and Infectious diseases, Amsterdam University Medical Centers, Emma Children's Hospital, Amsterdam, The Netherlands.

Objectives: Rituximab (RTX) is a chimeric monoclonal CD20-antibody. Lack of efficacy has been suggested to be related to the presence of anti-drug antibodies (ADA). The aims of this study were to determine if ADA impact the pharmacokinetics (PK) and pharmacodynamics (PD) of RTX in children, whether the formation of ADA differs between various immune-mediated diseases and if it is related to the occurrence of infusion-related reactions (IRR). Read More

View Article and Full-Text PDF

Lenalidomide and Rituximab Regimen Combined With Intravitreal Methotrexate Followed by Lenalidomide Maintenance for Primary Vitreoretinal Lymphoma: A Prospective Phase II Study.

Front Oncol 2021 24;11:701507. Epub 2021 Jun 24.

Department of Ophthalmology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China.

Primary vitreoretinal lymphoma (PVRL) is a rare variant of primary central nervous system (CNS) lymphoma, for which currently there are no optimal treatment options. This prospective single-center study enrolled immunocompetent patients with newly diagnosed PVRL between August 2018 and January 2020. Patients received local and systemic therapies: intravitreal methotrexate (MTX, 400 μg, 0. Read More

View Article and Full-Text PDF

Biologics in autoimmune bullous diseases: Current scenario.

Indian J Dermatol Venereol Leprol 2021 Jul 7:1-10. Epub 2021 Jul 7.

Department of Dermatology, Venereology and Leprology, Postgraduate Institute of Medical Education and Research, Chandigarh, India.

Autoimmune bullous diseases can be intraepidermal (pemphigus group of disorders) or subepidermal (pemphigoid group of disorders). The treatment of these disorders chiefly comprises corticosteroids and immunosuppressant adjuvants like azathioprine and mycophenolate mofetil. Autoantibodies are the main mediators of these diseases. Read More

View Article and Full-Text PDF

Efficacy and safety of rituximab for IgG4-related pancreato-biliary disease: A systematic review and meta-analysis.

Pancreatology 2021 Jul 3. Epub 2021 Jul 3.

Division of Pancreatic Surgery and Endosonography Division, Pancreas Translational and Clinical Research Center, IRCCS San Raffaele Scientific Institute, Milan, Italy.

Background: Type I autoimmune pancreatitis (AIP) and IgG4-related sclerosing cholangitis (IgG4-SC) belong to the IgG4-related disease (IgG4-RD) spectrum. Both entities respond to glucocorticoids, but iatrogenic toxicity associated with prolonged steroid therapy and relapse represent relevant clinical concerns in the long-term. Rituximab is increasingly used as an effective alternative strategy to induce remission but data regarding the safety and efficacy of B-cell depletion therapy for pancreato-biliary involvement of IgG4-RD are limited. Read More

View Article and Full-Text PDF

A novel approach to a rare case of non-islet cell hypoglycaemia.

Endocrinol Diabetes Metab Case Rep 2021 Jul 1;2021. Epub 2021 Jul 1.

Diabetes and Vascular Medicine Department, Monash Health, Victoria, Australia.

Summary: Insulin autoimmune syndrome (IAS) is a rare cause of non-islet cell hypoglycaemia. Treatment of this condition is complex and typically involves long-term use of glucocorticoids. Immunotherapy may provide an alternative in the management of this autoimmune condition through the suppression of antibodies production by B-lymphocyte depletion. Read More

View Article and Full-Text PDF

B cell depletion impairs vaccination-induced CD8 T cell responses in a type I interferon-dependent manner.

Ann Rheum Dis 2021 Jul 5. Epub 2021 Jul 5.

Institute for Experimental Infection Research, TWINCORE, Centre for Experimental and Clinical Infection Research, a joint venture between the Hannover Medical School and the Helmholtz Centre for Infection Research, Hanover, Germany

Objectives: The monoclonal anti-CD20 antibody rituximab is frequently applied in the treatment of lymphoma as well as autoimmune diseases and confers efficient depletion of recirculating B cells. Correspondingly, B cell-depleted patients barely mount de novo antibody responses during infections or vaccinations. Therefore, efficient immune responses of B cell-depleted patients largely depend on protective T cell responses. Read More

View Article and Full-Text PDF

[Cohort study of efficacy and safety of polatuzumab vedotin combined with immunochemotherapy in patients with relapse/refractory diffuse large B cell lymphoma].

Zhonghua Yi Xue Za Zhi 2021 Jul;101(25):1985-1990

Department of Medical Oncology, Jiangsu Cancer Hospital, Jiangsu Institute of Cancer Research/the Affiliated Cancer Hospital of Nanjing Medical University, Nanjing 210009, China.

To investigate the efficacy and tolerability of Polatuzumab vedotin+rituximab±bendamustine (Pola-(B)R) in relapse/refractory diffuse large B cell lymphoma (R/R DLBCL) patients. The clinical data of 21 patients enrolled in Chinese Pola compassionate use program (CUP) in 4 centers from November 2019 to August 2020 were collected. There were 15 males and 6 females, and the median age was 56 years (ranged 25-76 years). Read More

View Article and Full-Text PDF

Membranous Nephropathy: It Is Time to Go Back to the Future.

Nephron 2021 Jul 5:1-7. Epub 2021 Jul 5.

Renal Division, ASST Santi Paolo e Carlo, Department of Health Sciences, University of Milan, Milan, Italy.

Context: Membranous nephropathy (MN) is an immune-mediated glomerular disease that can lead to nephrotic syndrome and progressive kidney function loss. The cyclic steroid-cyclophosphamide regimen (the modified Ponticelli protocol) and the monoclonal anti-CD20 antibody rituximab have been advocated as effective therapies to improve renal outcomes, but a direct comparison of these treatments had never been carried out in a prospective study. Subject of Review: Scolari et al. Read More

View Article and Full-Text PDF

Immune Thrombocytopenia Revealing Enriched IgG-4 Peri-Renal Rosai-Dorfman Disease Successfully Treated with Rituximab: A Case Report and Literature Review.

Front Med (Lausanne) 2021 16;8:678456. Epub 2021 Jun 16.

Sorbonne Université, Assistance Publique Hôpitaux de Paris, Pitié-Salpêtrière Hospital, Internal Medicine Department 2, National Reference Center for Histiocytosis, Paris, France.

Immune thrombocytopenia (ITP) is a rare autoimmune-mediated condition characterized by isolated thrombocytopenia (<100 G/L) after exclusion of other causes. Mostly primary, it is associated with hematological malignancy, autoimmune disorders, or infection in 20% of patients. It is exceptionally described in patients with histiocytosis, mostly in children (seven patients in literature). Read More

View Article and Full-Text PDF